Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HJ891 plus toripalimab in first-line KRAS G12C-mutated non-squamous NSCLC
CTR20240054Phase 3Active
- Sponsor
- Huajian Future
- Start
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HJ891, toripalimab in Non-small cell lung cancer (NS-NSCLC), non-small cell lung cancer (NSCLC), sponsored by Huajian Future. Started Jan 2024; status: active.
02
Drugs
HJ891toripalimab
03
Conditions
Non-small cell lung cancer (NS-NSCLC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20240054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240054.